person · Reporting owner

Aryeh Jason

Disclosed activity across 8 companies

Tapewire entity: 35404
SEC CIK: 0001376960

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617	Director	April 04, 2025	April 08, 2025
Aralez Pharmaceuticals Inc.ARLZ · Entity 165961	Director	May 19, 2017	May 24, 2017
IMMUNOMEDICS INCIMMU · Entity 145732	Director	January 08, 2017	January 10, 2017
LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447	Director	June 04, 2026	June 05, 2026
LIGAND PHARMACEUTICALS INCLGND · Entity 3825	Director	June 05, 2026	June 12, 2026
MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770	10% owner · See Explanation of Responses	July 16, 2019	July 18, 2019
NOVELION THERAPEUTICS INC.NVLN · Entity 152369	Director	May 15, 2017	May 17, 2017
Orchestra BioMed Holdings, Inc.OBIO · Entity 434	Director	June 23, 2026	June 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Anebulo Pharmaceuticals, Inc.

Report date April 04, 2025 · Filed April 08, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03	Direct	25,000	Reported balance After 2025-04-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-04-04 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03	Direct	4,964	Reported balance After 2025-04-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-04-04 · Grant · Acquired 4,964 · Balance 4,964 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders.

Aralez Pharmaceuticals Inc.

Report date May 19, 2017 · Filed May 24, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, without par valueSEC Table I · non-derivative	IndirectBy JALAA Equities, LP	337,644	Reported balance After 2017-05-19 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-05-19 · Sale · Disposed 51,041 · Balance 337,644 F1: This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Includes 45,469 shares issued in connection with a previously exercised warrant. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.
Common Shares, without par valueSEC Table I · non-derivative	IndirectBy JALAA Equities, LP	104,176	Reported balance After 2017-05-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-05-22 · Sale · Disposed 233,468 · Balance 104,176 F4: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.
Common Shares, without par valueSEC Table I · non-derivative	IndirectBy JALAA Equities, LP	0	Reported balance After 2017-05-23 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-05-23 · Sale · Disposed 104,176 · Balance 0 F5: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.
Common Shares, without par valueSEC Table I · non-derivative	Direct	15,000	Reported balance Holding disclosure · report date 2017-05-19 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 15,000

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Includes 45,469 shares issued in connection with a previously exercised warrant.

F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.

F4: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

IMMUNOMEDICS INC

Report date January 08, 2017 · Filed January 10, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2024-01-08	Direct	22,500	Reported balance After 2017-01-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-01-08 · Grant · Acquired 22,500 · Balance 22,500

LIFECORE BIOMEDICAL, INC. \DE\

Report date June 04, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	69,967	Reported balance After 2026-06-04 transaction · row 1 1 source row Row 1 · 2026-06-04 · Grant · Acquired 25,907 · Balance 69,967 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

LIGAND PHARMACEUTICALS INC

Report date June 05, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	107,580	Reported balance After 2026-06-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 836 · Balance 107,580 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. F2: The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records.
Common StockSEC Table I · non-derivative	Direct	107,080	Reported balance After 2026-06-10 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-06-10 · Sale · Disposed 500 · Balance 107,080
Common StockSEC Table I · non-derivative	Direct	102,580	Reported balance After 2026-06-11 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2026-06-11 · Sale · Disposed 4,500 · Balance 102,580
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.00 · Expires 2036-06-05	Direct	2,938	Reported balance After 2026-06-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-05 · Grant · Acquired 2,938 · Balance 2,938 F4: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Common StockSEC Table I · non-derivative	IndirectIndirect	13,000	Reported balance Holding disclosure · report date 2026-06-05 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 13,000 F3: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

F2: The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records.

F3: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.

F4: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

MERRIMACK PHARMACEUTICALS INC

Report date July 16, 2019 · Filed July 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,802	Reported balance After 2019-07-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2019-07-16 · Purchase · Acquired 302 · Balance 3,802 F1: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

NOVELION THERAPEUTICS INC.

Report date May 15, 2017 · Filed May 17, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	242,433	Reported balance After 2017-05-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-05-15 · Purchase · Acquired 361 · Balance 242,433 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
Common SharesSEC Table I · non-derivative	IndirectBy JALAA Equities, L.P.	127,491	Reported balance Holding disclosure · report date 2017-05-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 127,491 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest.
Common SharesSEC Table I · non-derivative	IndirectBy JLV Investments, LP	6,256	Reported balance Holding disclosure · report date 2017-05-15 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 6,256 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest.
Common SharesSEC Table I · non-derivative	IndirectBy JLD Investments, L.P.	16,553	Reported balance Holding disclosure · report date 2017-05-15 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 16,553 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.

F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest.

Orchestra BioMed Holdings, Inc.

Report date June 23, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2036-06-23	Direct	42,553	Reported balance After 2026-06-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-23 · Grant · Acquired 42,553 · Balance 42,553 F1: The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 23, 2026 Filed Jun 25, 2026 20:16 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantStock Option (Right to Buy) · Derivative	42,553	$0.00 Strike: $4.04	$0.00	Disclosure SEC source: 0001104659-26-077771 · tm2618965-2_4seq1.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,553 Underlying: Common Stock · 42,553 shares Expires 2036-06-23 F1 · derivative.exercise_date: The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date. Read SEC document
June 11, 2026 Filed Jun 12, 2026 21:27 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	4,500	$250.00	$1,125,000.00	Disclosure SEC source: 0002001011-26-000103 · edgardoc.xml · nonDerivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,580 Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:27 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	500	$250.00	$125,000.00	Disclosure SEC source: 0002001011-26-000103 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,080 Read SEC document
June 05, 2026 Filed Jun 12, 2026 21:27 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantNon-Qualified Stock Option (right to buy) · Derivative	2,938	$0.00 Strike: $237.00	$0.00	Disclosure SEC source: 0002001011-26-000103 · edgardoc.xml · derivative · entry 5 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,938 Underlying: Common Stock · 2,938 shares Expires 2036-06-05 F4 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
June 05, 2026 Filed Jun 12, 2026 21:27 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	836	$0.00	$0.00	Disclosure SEC source: 0002001011-26-000103 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,580 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. F2 · balance_after: The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records. Read SEC document
June 04, 2026 Filed Jun 5, 2026 20:46 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantCommon Stock	25,907	Not disclosed	Not disclosed	Disclosure SEC source: 0001376960-26-000002 · wk-form4_1780692392.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,967 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). Read SEC document
May 18, 2026 Filed May 20, 2026 12:00 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	PurchaseCommon Stock, par value $0.0001 per share	665	$3.75	$2,493.75	Disclosure SEC source: 0001104659-26-064136 · tm2615140-1_4seq1.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,118 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.75 to $3.76. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
May 15, 2026 Filed May 19, 2026 12:00 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	PurchaseCommon Stock, par value $0.0001 per share	8,971	$3.90	$34,986.90	Disclosure SEC source: 0001104659-26-063511 · tm2614983-1_4seq1.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,453 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $4.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
December 08, 2025 Filed Dec 9, 2025 00:38 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,034	$0.00 Strike: $69.51	$0.00	Disclosure SEC source: 0002001011-25-000122 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,034 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2016, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document
December 08, 2025 Filed Dec 9, 2025 00:38 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	2,034	$69.51	$141,383.34	Disclosure SEC source: 0002001011-25-000122 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 23, 2025 Filed Sep 24, 2025 21:11 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	954	$171.92	$164,015.21	Disclosure SEC source: 0002001011-25-000082 · edgardoc.xml · nonDerivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,289 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $171.7250 to $172.2400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 23, 2025 Filed Sep 24, 2025 21:11 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	4,628	$170.96	$791,222.78	Disclosure SEC source: 0002001011-25-000082 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,243 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $170.6850 to $171.6050. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 23, 2025 Filed Sep 24, 2025 21:11 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	4,418	$170.41	$752,849.73	Disclosure SEC source: 0002001011-25-000082 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,871 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $169.6625 to $170.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 19, 2025 Filed Sep 19, 2025 22:57 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	PurchaseCommon Stock, par value $0.0001 per share	1,000	$2.45	$2,450.00	Disclosure SEC source: 0001104659-25-091775 · tm2526559-7_4seq1.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,482 Read SEC document
August 07, 2025 Filed Aug 8, 2025 23:17 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	15,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-075788 · tm2523004-9_4seq1.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,482 F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date. Read SEC document
July 15, 2025 Filed Jul 17, 2025 20:43 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantCommon Stock	19,506	Not disclosed	Not disclosed	Disclosure SEC source: 0001005286-25-000091 · wk-form4_1752784972.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,060 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than 50 weeks from the date hereof). Read SEC document
June 24, 2025 Filed Jun 27, 2025 21:09 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantStock Option (Right to Buy) · Derivative	36,797	$0.00 Strike: $3.22	$0.00	Disclosure SEC source: 0001104659-25-063692 · tm2519252-4_4seq1.xml · derivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,797 Underlying: Common Stock · 36,797 shares Expires 2035-06-24 F2 · derivative.exercise_date: The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates. Read SEC document
June 24, 2025 Filed Jun 27, 2025 21:09 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	12,422	$0.00	$0.00	Disclosure SEC source: 0001104659-25-063692 · tm2519252-4_4seq1.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,482 F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates. Read SEC document
June 06, 2025 Filed Jun 10, 2025 23:39 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantNon-Qualified Stock Option (right to buy) · Derivative	5,783	$0.00 Strike: $105.99	$0.00	Disclosure SEC source: 0002001011-25-000045 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,783 Underlying: Common Stock · 5,783 shares Expires 2035-06-06 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
June 06, 2025 Filed Jun 10, 2025 23:39 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	1,209	$0.00	$0.00	Disclosure SEC source: 0002001011-25-000045 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,289 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
April 04, 2025 Filed Apr 8, 2025 01:41 UTC	Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617	GrantStock Option (right to buy) · Derivative	4,964	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0001641172-25-003092 · ownership.xml · derivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,964 Underlying: Common Stock · 4,964 shares Expires 2035-04-03 F1 · derivative.exercise_date: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. Read SEC document
April 04, 2025 Filed Apr 8, 2025 01:41 UTC	Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0001641172-25-003092 · ownership.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-04-03 F1 · derivative.exercise_date: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. Read SEC document
December 27, 2024 Filed Dec 30, 2024 23:09 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Exercise / conversionStock Option (Right to Buy) · Derivative	11,700	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001104659-24-132582 · tm2432271-1_4seq1.xml · derivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 11,700 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 27, 2024 Filed Dec 30, 2024 23:09 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock")	11,700	$4.30	$50,310.00	Disclosure SEC source: 0001104659-24-132582 · tm2432271-1_4seq1.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 19, 2024 Filed Aug 21, 2024 23:54 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantCommon Stock	24,554	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-038090 · wk-form4_1724284438.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,554 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024). Read SEC document
June 20, 2024 Filed Jun 21, 2024 21:56 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantStock Option (Right to Buy) · Derivative	17,068	$0.00 Strike: $7.44	$0.00	Disclosure SEC source: 0001104659-24-074012 · tm2417742-4_4seq1.xml · derivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2034-06-20 Read SEC document
June 20, 2024 Filed Jun 21, 2024 21:56 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	5,376	$0.00	$0.00	Disclosure SEC source: 0001104659-24-074012 · tm2417742-4_4seq1.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,360 F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 20, 2024. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on June 20, 2025. Read SEC document
June 14, 2024 Filed Jun 19, 2024 01:25 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantNon-Qualified Stock Option (right to buy) · Derivative	5,444	$0.00 Strike: $80.06	$0.00	Disclosure SEC source: 0002001011-24-000055 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,444 Underlying: Common Stock · 5,444 shares Expires 2034-06-14 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
June 14, 2024 Filed Jun 19, 2024 01:25 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	1,252	$0.00	$0.00	Disclosure SEC source: 0002001011-24-000055 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,080 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
June 13, 2024 Filed Jun 17, 2024 20:23 UTC	Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617	GrantStock Option (right to buy) · Derivative	2,482	$0.00 Strike: $2.10	$0.00	Disclosure SEC source: 0001493152-24-024123 · ownership.xml · derivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,482 Underlying: Common Stock · 2,482 shares Expires 2034-06-12 F2 · derivative.exercise_date: These stock options vest on the earlier of November 30,2024 or the date of the 2024 annual meeting of shareholders Read SEC document
June 13, 2024 Filed Jun 17, 2024 20:23 UTC	Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617	GrantStock Option (right to buy) · Derivative	41,667	$0.00 Strike: $2.10	$0.00	Disclosure SEC source: 0001493152-24-024123 · ownership.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 41,667 shares Expires 2034-06-12 F1 · derivative.exercise_date: These stock options vest 50% on the date of the 2024 annual meeting of shareholders and 50% on the one year anniversary of the date of grant Read SEC document
April 30, 2024 Filed May 2, 2024 22:07 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,406	$0.00 Strike: $52.30	$0.00	Disclosure SEC source: 0002001011-24-000050 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,406 shares Expires 2025-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This Option was previously reported as a Grant of 2,754 shares, which vested in full on April 24, 2016, at an exercise price of $89.75 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document
April 30, 2024 Filed May 2, 2024 22:07 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	2,406	$52.30	$125,833.80	Disclosure SEC source: 0002001011-24-000050 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 05, 2024 Filed Mar 6, 2024 22:28 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,893	$0.00 Strike: $39.35	$0.00	Disclosure SEC source: 0002001011-24-000032 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,893 shares Expires 2024-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This Option was previously reported as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document
March 05, 2024 Filed Mar 6, 2024 22:28 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	2,893	$39.35	$113,839.55	Disclosure SEC source: 0002001011-24-000032 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 20, 2023 Filed Jul 24, 2023 22:03 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $7.42	$0.00	Disclosure SEC source: 0001104659-23-083523 · tm2321855-3_4seq1.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-07-20 Read SEC document
June 09, 2023 Filed Jun 13, 2023 22:54 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantNon-Qualified Stock Option (right to buy) · Derivative	5,461	$0.00 Strike: $73.76	$0.00	Disclosure SEC source: 0000886163-23-000040 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,461 Underlying: Common Stock · 5,461 shares Expires 2033-06-09 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
June 09, 2023 Filed Jun 13, 2023 22:54 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	1,142	$0.00	$0.00	Disclosure SEC source: 0000886163-23-000040 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,529 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
April 12, 2023 Filed May 6, 2023 00:16 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Exercise / conversionRight to Receive Earnout Shares · Derivative	11,246	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-037023 · ownership.xml · derivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,246 Underlying: Common Stock · 11,246 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document
April 12, 2023 Filed May 6, 2023 00:16 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock")	11,246	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-037023 · ownership.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:31 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantNonstatutory Stock Option (Right to Buy) · Derivative	23,250	Not disclosed Strike: $10.00	Not disclosed	Disclosure SEC source: 0001213900-23-006188 · ownership.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-25 F6 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share. F5 · derivative.exercise_date: The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis on the day of the month of each quarter that is the same day of the month as the grant date, starting with the corresponding date in the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:31 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantNonstatutory Stock Option (Right to Buy) · Derivative	6,975	Not disclosed Strike: $4.30	Not disclosed	Disclosure SEC source: 0001213900-23-006188 · ownership.xml · derivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock · 6,975 shares Expires 2029-08-06 F4 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 15,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:31 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantNonstatutory Stock Option (Right to Buy) · Derivative	18,600	Not disclosed Strike: $4.30	Not disclosed	Disclosure SEC source: 0001213900-23-006188 · ownership.xml · derivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2028-11-16 F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 40,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:31 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	51,738	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-006188 · ownership.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,738 F1 · shares: These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities. F2 · price: Received in the Business Combination in exchange for 111,263 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock"). Read SEC document
January 26, 2023 Filed May 5, 2023 23:50 UTC Amendment	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantRight to Receive Earnout Shares · Derivative	22,492	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-037006 · ownership.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,492 Underlying: Common Stock · 22,492 shares Expires not disclosed F1 · security: On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently omitted the right to receive Earnout Shares (defined below). In accordance with Instruction 9(a) to Form 4, this amendment is filed solely to add the lines of information to Table II included here; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing. F2 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. Read SEC document
January 26, 2023 Filed May 19, 2023 21:42 UTC Amendment	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantNonstatutory Stock Option (Right to Buy) · Derivative	23,250	Not disclosed Strike: $10.00	Not disclosed	Disclosure SEC source: 0001213900-23-041619 · ownership.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-17 F1 · security: On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently misstated the expiration date of one class of nonstatutory stock options ("NSOs"). In accordance with Instruction 9(b) to Form 4, this amendment is filed solely to correct the incorrect expiration date in Table II, Column 6 to August 17, 2032; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing. F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share. F2 · derivative.exercise_date: The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis on the day of the month of each quarter that is the same day of the month as the grant date, starting with the corresponding date in the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document
December 22, 2022 Filed Dec 27, 2022 23:26 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantNon-Qualified Stock Option (right to buy) · Derivative	4,484	$0.00 Strike: $67.03	$0.00	Disclosure SEC source: 0000899243-22-039401 · doc4.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,484 Underlying: Common Stock · 4,484 shares Expires 2032-12-22 F1 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023. Read SEC document
June 10, 2022 Filed Jun 13, 2022 22:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantNon-Qualified Stock Option (right to buy) · Derivative	4,340	$0.00 Strike: $79.29	$0.00	Disclosure SEC source: 0000886163-22-000085 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,340 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
June 10, 2022 Filed Jun 13, 2022 22:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	1,004	$0.00	$0.00	Disclosure SEC source: 0000886163-22-000085 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,668 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document
April 21, 2022 Filed Oct 3, 2022 23:53 UTC	Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617	GrantStock Option (right to buy) · Derivative	30,425	$0.00 Strike: $6.00	$0.00	Disclosure SEC source: 0001209191-22-051982 · doc4.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,425 Underlying: Common Stock · 30,425 shares Expires 2027-02-28 F1 · derivative.exercise_date: 25% of the option vests on March 1, 2023. Thereafter, 1/48 of the option vests on a monthly basis over 36 months until the option becomes fully vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.